secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001641172-25-016285
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA reports preclinical data for SKNY-1: biased CB1 modulation, CB2 activity, selective MAO-B inhibition
--------------------------------------------------------------------------------

- SKNY-1 shows biased CB1 antagonism: blocks β-arrestin (cravings) but spares G-protein (mood stability), unlike rimonabant.
- Partial agonist at CB2 receptor, targeting metabolic regulation and inflammation for obesity comorbidities.
- Selective MAO-B inhibition; no MAO-A or D1/D2/D3 dopamine receptor activity, supporting CNS safety.
- Data from Eurofins in vitro studies; in vivo animal models for weight loss and nicotine addiction are being finalized.
- Acquisition of SKNY by MIRA remains subject to regulatory and shareholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/0001641172-25-016285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer